
Sellas Life Sciences (SLS) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 303.4%.
| ASSET | % RETURN |
|---|---|
Sellas Life Sciences (SLS) | 303.37% |
CareDx (CDNA) | 295.12% |
Erasca (ERAS) | 270.89% |
Veradermics (MANE) | 267.24% |
Twist Bioscience (TWST) | 266.69% |
Kodiak Sciences (KOD) | 250.45% |
10X Genomics (TXG) | 249.91% |
TOP Financial (TOP) | 237.82% |
Immunitybio (IBRX) | 231.68% |
Pulse Biosciences (PLSE) | 231.38% |
Abcellera Biologics (ABCL) | 222.22% |
Oruka Therapeutics (ORKA) | 215.87% |
Spyre Therapeutics (SYRE) | 209.71% |
Okeanis Eco Tankers (ECO) | 194.02% |
Enliven Therapeutics (ELVN) | 189.61% |
MaxLinear (MXL) | 177.79% |
Iovance Biotherapeutics (IOVA) | 169.06% |
Acadia Healthcare (ACHC) | 162.87% |
Iridium Communications (IRDM) | 156.38% |
Tango Therapeutics (TNGX) | 147.34% |
Ringcentral (RNG) | 147.27% |
Hinge Health (HNGE) | 146.62% |
Sezzle (SEZL) | 145.75% |
Cheesecake Factory (CAKE) | 140.77% |
MSG Knickerbockers (MSGK) | 135.99% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.